Fuda Cancer Hospital
The cost of radiation therapy for colorectal cancer in China typically ranges from $11,500 to $27,500. The total investment depends on the chosen radiation technology, facility tier, and treatment duration. Patients save around 44% compared to the US, where this procedure costs $35,000 on average. Major medical hubs for this treatment include Guangzhou, Shanghai, and Beijing.
Bookimed Expert Insight: Choosing JCI-accredited facilities like Fuda Cancer Hospital provides international safety standards at local prices. Highly experienced specialists, such as those with 30 years of practice like Dr. Zhang Yanjun, often have Western training. This expertise is particularly valuable for complex primary or secondary tumors. Patients should prioritize hospitals in Guangzhou or Shanghai for the most competitive advanced radiotherapy options.
| China | Turkey | Austria | |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
No hidden fees – just official clinic prices. Pay at the clinic for Radiation therapy for colorectal cancer upon arrival and use a flexible installment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Radiation therapy for colorectal cancer and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Radiation therapy for colorectal cancer journey.
Day 1
Day 2-3
Day 4-5
Day 6
Week 2-6
Week 7
Week 8
Week 12
Week 16
Please note that this is a general timeline and each patient"s case is unique. The duration and specifics of treatment and recovery may vary.
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
30 years specializing in tumor imaging diagnosis gedailleung and radiation therapy – Dr. Zhang has treated thousands of cases at Jinshazhou Hospital.
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Involves using high-energy rays to target and destroy cancer cells in the colon or rectum.